1. Home
  2. TRIB vs CYTH Comparison

TRIB vs CYTH Comparison

Compare TRIB & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRIB
  • CYTH
  • Stock Information
  • Founded
  • TRIB 1992
  • CYTH 1990
  • Country
  • TRIB Ireland
  • CYTH United States
  • Employees
  • TRIB N/A
  • CYTH N/A
  • Industry
  • TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • CYTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • TRIB Health Care
  • CYTH Health Care
  • Exchange
  • TRIB Nasdaq
  • CYTH Nasdaq
  • Market Cap
  • TRIB 24.0M
  • CYTH 26.2M
  • IPO Year
  • TRIB N/A
  • CYTH N/A
  • Fundamental
  • Price
  • TRIB $0.77
  • CYTH $0.80
  • Analyst Decision
  • TRIB
  • CYTH Buy
  • Analyst Count
  • TRIB 0
  • CYTH 3
  • Target Price
  • TRIB N/A
  • CYTH $0.95
  • AVG Volume (30 Days)
  • TRIB 258.9K
  • CYTH 56.4K
  • Earning Date
  • TRIB 11-15-2024
  • CYTH 03-17-2025
  • Dividend Yield
  • TRIB N/A
  • CYTH N/A
  • EPS Growth
  • TRIB N/A
  • CYTH N/A
  • EPS
  • TRIB N/A
  • CYTH N/A
  • Revenue
  • TRIB $59,126,000.00
  • CYTH $870,725.00
  • Revenue This Year
  • TRIB $11.63
  • CYTH N/A
  • Revenue Next Year
  • TRIB $10.13
  • CYTH $24.49
  • P/E Ratio
  • TRIB N/A
  • CYTH N/A
  • Revenue Growth
  • TRIB N/A
  • CYTH N/A
  • 52 Week Low
  • TRIB $0.75
  • CYTH $0.55
  • 52 Week High
  • TRIB $3.55
  • CYTH $2.12
  • Technical
  • Relative Strength Index (RSI)
  • TRIB 38.04
  • CYTH 64.58
  • Support Level
  • TRIB $0.75
  • CYTH $0.76
  • Resistance Level
  • TRIB $1.04
  • CYTH $0.72
  • Average True Range (ATR)
  • TRIB 0.08
  • CYTH 0.07
  • MACD
  • TRIB 0.01
  • CYTH 0.02
  • Stochastic Oscillator
  • TRIB 7.83
  • CYTH 79.38

About TRIB Trinity Biotech plc

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

About CYTH Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

Share on Social Networks: